Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human BMI1 Anticorps:
anti-Mouse (Murine) BMI1 Anticorps:
anti-Rat (Rattus) BMI1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal BMI1 Primary Antibody pour BI, IHC (f) - ABIN2688857
Dimri, Martinez, Jacobs, Keblusek, Itahana, Van Lohuizen, Campisi, Wazer, Band: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. dans Cancer research 2002
Show all 6 Pubmed References
Human Polyclonal BMI1 Primary Antibody pour FACS, IF - ABIN652702
Chagraoui, Niessen, Lessard, Girard, Coulombe, Sauvageau, Meloche, Sauvageau: E4F1: a novel candidate factor for mediating BMI1 function in primitive hematopoietic cells. dans Genes & development 2006
Show all 4 Pubmed References
Human Monoclonal BMI1 Primary Antibody pour ICC, FACS - ABIN968985
Edwards, Witherspoon, Wang, Afrasiabi, Pham, Birnbaumer, Lipkin: Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. dans Cancer research 2009
Show all 2 Pubmed References
Human Monoclonal BMI1 Primary Antibody pour ChIP - ABIN2668619
Lafkas, Rodilla, Huyghe, Mourao, Kiaris, Fre: Notch3 marks clonogenic mammary luminal progenitor cells in vivo. dans The Journal of cell biology 2013
Show all 2 Pubmed References
Human Monoclonal BMI1 Primary Antibody pour ELISA, WB - ABIN560071
Andrews, Banting, Damjanov, Arnaud, Avner: Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. dans Hybridoma 1985
Show all 2 Pubmed References
Human Polyclonal BMI1 Primary Antibody pour IHC (fro), WB - ABIN2477677
Mandal, Boitano, Maxwell, Lou, Alexander: Ninety-eight penetrating vascular injuries: a review of a two and one-half year experience. dans The Journal of trauma 1976
Show all 3 Pubmed References
Human Polyclonal BMI1 Primary Antibody pour ICC, IF - ABIN152245
Kang, Qi, Zuo, Wang, Zou, Schwartz, Cheng, Yeh: SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. dans Molecular cell 2010
Human Polyclonal BMI1 Primary Antibody pour ICC, IF - ABIN257760
Ismail, Andrin, McDonald, Hendzel: BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. dans The Journal of cell biology 2010
Human Monoclonal BMI1 Primary Antibody pour CyTOF, FACS - ABIN4900505
Shen, Chen, Ding, Qi, Cen, Wang, Yao, Chen: BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression. dans Journal of cellular and molecular medicine 2014
Human Monoclonal BMI1 Primary Antibody pour ChIP, ICC - ABIN4284857
Courel, Friesenhahn, Lees: E2f6 and Bmi1 cooperate in axial skeletal development. dans Developmental dynamics : an official publication of the American Association of Anatomists 2008
Upregulation of BMI1 correlates with advanced stages of breast neoplasm, poor prognosis and resistance to radiation and chemotherapy. BMI1 seems to be a key player in EMT (Montrer ITK Anticorps), chemo-resistance and cancer stemness. Studies showed that reduction of BMI protein level in tumor cells results in inhibition of cell proliferation, induction of apoptosis, and increases susceptibility to cytotoxic agents and radiation therapy. [review]
Down-regulating Bmi-1 may inhibit the biological properties of CD133+ LCSC by blocking NF-kappaB (Montrer NFKB1 Anticorps) signaling pathway, which lays a scientific foundation for the clinical treatment of liver cancer.
BMI1 expression is not associated with Colorectal Cancer.
these findings provide further evidence on the tumor-suppression function of miR (Montrer MLXIP Anticorps)-630 in breast cancer, and clarify BMI1 as a novel functional target gene of miR (Montrer MLXIP Anticorps)-630.
BMI1 is a potential biomarker in epithelial ovarian cancermanagement, especially for tumor progression and chemo-resistance. Molecular traits, including BMI1 and core genes in Focal adhesion and PI3K (Montrer PIK3CA Anticorps)/AKT (Montrer AKT1 Anticorps) pathways, might be alternatives as therapeutic targets for EOC.
Through radiotherapy and chemotherapy assays, the function of miR (Montrer MLXIP Anticorps)-128a on chemoradiotherapy was evaluated. The correlation of miR (Montrer MLXIP Anticorps)-128a with BMI1 was identified by performing real-time PCR.
Study demonstrated that BMI-1 was overexpressed in oesophageal squamous cell cancer (ESCC) cells and was related to poor prognosis in ESCC patients. Its knockdown induces radiosensitivity in ESCC and significantly inhibits cell viability, which may contribute to an increased proportion of cells in the G0/G1 phase and cell apoptosis via suppression of the PI3K (Montrer PIK3CA Anticorps)/Akt (Montrer AKT1 Anticorps) signaling pathway.
Interaction of BMI1 with polyhomeotic protein PHC2 (Montrer PhC2 Anticorps) and homo-oligomerization via ubiquitin-like domain are necessary for H2A ubiquitination activity of PRC1 (Montrer PRC1 Anticorps) and for clonogenic potential of U2OS cells.
ur results reveal that miR (Montrer MLXIP Anticorps)-203a may regulate cholesteatoma growth and proliferation by targeting Bmi1. These findings provide insight for the development of novel nonsurgical options for cholesteatoma.
that the down-regulated Bmi-1 might inhibit the proliferation, invasion, and migration of gastrointestinal stromal tumor cells
Bmi1 is a marker for a distinct population of castration-resistant luminal epithelial cells enriched in the proximal prostate that can serve as a cell of origin for prostate cancer
Findings extend current knowledge of the role of BMI1 and CHD7 (Montrer CHD3 Anticorps) in medulloblastoma pathogenesis, and they raise the possibility that pharmacological targeting of BMI1 or ERK (Montrer EPHB2 Anticorps) may be particularly indicated in a subgroup of MB with low expression levels of CHD7 (Montrer CHD3 Anticorps)
Many Bmi1-positive cells within the tongue cancer specimens failed to proliferate.
High Expressions of BMI1 is associated with breast cancer.
of Bmi1 in lymphocytes can stimulate osteogenesis in vivo and partially rescue defects in skeletal growth and osteogenesis.
miR (Montrer MLXIP Anticorps)-203 is repressed by EZH2 (Montrer EZH2 Anticorps) in both embryonic and adult neural stem/progenitor cells (NSPCs). MiR (Montrer MLXIP Anticorps)-203 negatively regulates the proliferation of NSPCs. One of PRC1 (Montrer PRC1 Anticorps) components, Bmi1, is a downstream target of miR (Montrer MLXIP Anticorps)-203 in NSPCs.
Data suggest BMI1 overexpression as a novel mechanism leading to EphA7 (Montrer EPHA7 Anticorps) inactivation via H3K27 trimethylation and DNA methylation (Montrer HELLS Anticorps) by which BMI-1 controls cell proliferation in the postnatal lateral ventricle wall.
Bmi1 plays an important role in regulating the proliferation of cochlear supporting cells.
Results from this study indicate that estrogen deficiency downregulates BMI-1 and subsequently increases ROS (Montrer ROS1 Anticorps), T cell activation, and RANKL (Montrer TNFSF11 Anticorps) production in T cells, thus enhancing osteoclastogenesis and accelerating bone loss.
ompounding a previously described Bmi1-transgene and Pten-deficiency prostate cancer mouse model with the Ezh2 (Montrer EZH2 Anticorps) transgene did not enhance tumour progression or drive metastasis formation. In conclusion, we here report the generation of a wildtype Ezh2 (Montrer EZH2 Anticorps) overexpression mouse model that allows for intravital surveillance of tissues with activated transgene
Bmi1 acts immediately downstream of CCAAT enhancer binding protein-alpha (Montrer CEBPA Anticorps) to regulate the survival and self-renewal of hematopoietic stem cells and contribute to the erythropoietic dysplasia.
Pig Bmi1 cDNA is 3,193 bp in length and consists of a 981 bp open reading frame, a 256 bp 5 (Montrer HSPD1 Anticorps)' untranslated region (UTR (Montrer UTS2R Anticorps)), and a 1,956 bp 3 (Montrer BST1 Anticorps)' UTR (Montrer UTS2R Anticorps). The transcript contains no signal peptides and there are no transmembrane regions in the pig Bmi1 coded protein.
Component of a Polycomb group (PcG) multiprotein PRC1- like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones\; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. In the PRC1 complex, it is required to stimulate the E3 ubiquitin-protein ligase activity of RNF2/RING2 (By similarity).
B lymphoma Mo-MLV insertion region 1 homolog
, murine leukemia viral (bmi-1) oncogene homolog
, polycomb complex protein BMI-1
, polycomb group RING finger protein 4
, polycomb group protein Bmi1
, ring finger protein 51
, BMI1 polycomb ring finger oncogene
, B lymphoma Mo-MLV insertion region 1
, polycomb group ring finger 4
, polycomb complex protein BMI-1-A
, polycomb group RING finger protein 4-A
, B lymphoma Mo-MLV insertion region
, Polycomb group RING finger protein 4-B
, polycomb complex protein BMI-1-B
, polycomb group RING finger protein 4-B
, oncoprotein BMI-1